Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils Henry Lin, MD, Kevin M Boesel, MD, Daniel T Griffith, MD, Calman Prussin,

Slides:

Advertisements

Similar presentations

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy Ravi S. Swamy, MD, Neha Reshamwala,

Advertisements

Serum granzymes and CD30 are increased in children's milk protein sensitive enteropathy and celiac disease Merja T. Augustin, MD, Jorma Kokkonen, MD,

Serum granzymes and CD30 are increased in children's milk protein sensitive enteropathy and celiac disease Merja T. Augustin, MD, Jorma Kokkonen, MD,

Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial David M. Fleischer, MD, A. Wesley Burks,

Alalia Berry, MD, William W. Busse, MD

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy Michael Kulis, PhD, Katie.

Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactose Scott P. Commins, MD, PhD, Hayley R. James,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Anti-IgE treatment of eosinophil-associated gastrointestinal disorders

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Increased expression of nuclear factor of activated T cells 1 drives IL-9–mediated allergic asthma Sonja Koch, PhD, Anna Graser, PhD, Hooman Mirzakhani,

Humanized mouse model of mast cell–mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis Paul J. Bryce, PhD, Rustom Falahati, PhD,

The Editors' Choice Journal of Allergy and Clinical Immunology

Omalizumab treatment downregulates dendritic cell FcεRI expression

Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy Pamela A. Frischmeyer-Guerrerio, MD,

The effect of omalizumab on nasal allergic inflammation

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis Friedrich Horak, MD, Kamal D.

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy Robert A.

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge Yee Ean Ong, MBBS, Andrew Menzies-Gow,

Analysis of basophil activation in patients with aspirin-exacerbated respiratory disease Chihiro Mitsui, MD, Keiichi Kajiwara, BSc, Emiko Ono, MD, PhD,

The enigma of IgE+ B-cell memory in human subjects

Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Experimental gastrointestinal allergy enhances pulmonary responses to specific and unrelated allergens Eric B. Brandt, PhD, Troy A. Scribner, MD, Hiroko.

Jerome A. Sigua, MD, Becky Buelow, MD, Dorothy S

Treatment of chronic autoimmune urticaria with omalizumab

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Daniel J. Jackson, MD, James E. Gern, MD, Robert F. Lemanske, MD

Biologics and biomarkers for asthma, urticaria, and nasal polyposis

A. Wesley Burks, MD, Robert A. Wood, MD, Stacie M. Jones, MD, Scott H

Donald W. MacGlashan, MD, PhD, Sarbjit S. Saini, MD

Decreases in human dendritic cell–dependent TH2-like responses after acute in vivo IgE neutralization John T. Schroeder, PhD, Anja P. Bieneman, BS, Kristin.

Early decreases in blood eosinophil levels with reslizumab

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial Hendrik.

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Barbara Foster, MSa, Lawrence B

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

John A. Eckman, MD, Patricia M

What is an “eosinophilic phenotype” of asthma?

Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses

Autophagy: Nobel Prize 2016 and allergy and asthma research

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis Thomas B. Casale, MD, William.

Thomas B. Casale, MDa, I. Leonard Bernstein, MDb, William W

House dust mite sublingual immunotherapy: Results of a US trial

Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection Marc Beyer, MD, Holger Bartz, MD, Katharina Hörner,

Sara Paveglio, PhD, MS, Erin Bennett, MS, Kelly L. Hawley, PhD, Adam P

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet Stephen.

Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5− TH2 responses Calman Prussin, MD, Joohee Lee,

Asifa K. Zaidi, PhD, Sarbjit S. Saini, MD, Donald W

Risk of oral food challenges

Chemical constituents of diesel exhaust particles induce IL-4 production and histamine release by human basophils Gilles Devouassoux, MDa, Andrew Saxon,

Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: Possible contribution to skin inflammation Takeshi Echigo, MD, Minoru Hasegawa,

Jessica H. Savage, MD, MHS, Elizabeth C. Matsui, MD, MHS, Robert A

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

Fiftieth Annual Meeting of the American Academy of Allergy and Immunology: Anaheim, California, March 1994 Lawrence M. Lichtenstein, MD, PhD Journal.

Dendritic cells in nasal mucosa of subjects with different allergic sensitizations Susanne M. Reinartz, MD, Joost van Tongeren, MD, Danielle van Egmond,

Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding Sven.

Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization Edwin H. Kim, MD, J. Andrew Bird, MD, Michael Kulis,

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma Oliver Noga, MD, Gerald Hanf, MD,

Systemic responses after bronchial aspirin challenge in sensitive patients with asthma Joanna S. Makowska, MD, PhD, Janina Grzegorczyk, PhD, Barbara Bienkiewicz,

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Analysis of basophil activation in patients with aspirin-exacerbated respiratory disease Chihiro Mitsui, MD, Keiichi Kajiwara, BSc, Emiko Ono, MD, PhD,

Advances in mechanisms of allergic disease in 2016

Presentation transcript:

Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils Henry Lin, MD, Kevin M Boesel, MD, Daniel T Griffith, MD, Calman Prussin, MD, Barbara Foster, MS, F.A Romero, MS, Robert Townley, MD, Thomas B Casale, MD Journal of Allergy and Clinical Immunology Volume 113, Issue 2, Pages 297-302 (February 2004) DOI: 10.1016/j.jaci.2003.11.044

FIG 1 Effect of omalizumab on nasal volume reduction after ragweed challenge. a, Omalizumab group showed significant blunting of reduction in nasal volume after PD30 dose of ragweed (P < .001) at each visit compared with baseline. b, In the placebo group, there was no statistical significance between visits to baseline and to each other. Data are medians ± 95% CIs (∗∗∗P < .001). Journal of Allergy and Clinical Immunology 2004 113, 297-302DOI: (10.1016/j.jaci.2003.11.044)

FIG 1 Effect of omalizumab on nasal volume reduction after ragweed challenge. a, Omalizumab group showed significant blunting of reduction in nasal volume after PD30 dose of ragweed (P < .001) at each visit compared with baseline. b, In the placebo group, there was no statistical significance between visits to baseline and to each other. Data are medians ± 95% CIs (∗∗∗P < .001). Journal of Allergy and Clinical Immunology 2004 113, 297-302DOI: (10.1016/j.jaci.2003.11.044)

FIG 2 Nasal challenge data on representative placebo-treated and omalizumab-treated subjects. The subject given placebo maintained a 30% reduction in nasal volume after ragweed nasal challenge compared with the subject given omalizumab, who had gradual blunted response to ragweed challenge, with onset at 7 to 14 days. Journal of Allergy and Clinical Immunology 2004 113, 297-302DOI: (10.1016/j.jaci.2003.11.044)

FIG 3 Basophil FACS plots. a, Flow cytometric dot plot shows gating used to identify the basophil population (polygon). b, Representative basophil FcεRI staining before study (open histogram) and on day 42 of omalizumab (shaded histogram). Journal of Allergy and Clinical Immunology 2004 113, 297-302DOI: (10.1016/j.jaci.2003.11.044)

FIG 4 Effects of omalizumab on basophil FcεRI. Percentage of baseline MFI, median ± 95% CI. a, Significant reduction in FcεRI on basophils at all time points vs baseline (P < .001, Tukey-Kramer) in the omalizumab-treated group. b, No significant change in FcεRI on basophils in the placebo-treated group. Journal of Allergy and Clinical Immunology 2004 113, 297-302DOI: (10.1016/j.jaci.2003.11.044)

FIG 4 Effects of omalizumab on basophil FcεRI. Percentage of baseline MFI, median ± 95% CI. a, Significant reduction in FcεRI on basophils at all time points vs baseline (P < .001, Tukey-Kramer) in the omalizumab-treated group. b, No significant change in FcεRI on basophils in the placebo-treated group. Journal of Allergy and Clinical Immunology 2004 113, 297-302DOI: (10.1016/j.jaci.2003.11.044)

FIG 5 Correlation of basophil FcεRIα expression with serum IgE. For each subject, the fraction of IgE and FcεRI while receiving omalizumab relative to day 0 baseline was determined and plotted as described in the Methods section. Journal of Allergy and Clinical Immunology 2004 113, 297-302DOI: (10.1016/j.jaci.2003.11.044)